Novavax claims effectiveness is 90% and will apply to the FDA for authorization

Research, editing : Gan Yung Chyan, KUCINTA SETIA

Like MVC-COV1901 and UBI covi vaccine, the United States Novavax vaccine is a subunit protein vaccine. According to multiple media reports in the United States, the company announced on Monday that the third phase of clinical trials in the United States and Mexico confirmed the safety and overall efficacy of 90.4%, and found that after two injections, Novavax can prevent 100% of the infected people from deteriorating to moderate to severe illness. Novavax plans to apply for authorization from the US Food and Drug Administration in the third quarter of 2021.

Refs: news.tvbs.com.tw/world/1527955?from=Copy_content, https://www.channelnewsasia.com/news/world/novavax-covid-19-vaccine-more-than-90-effective-in-us-trial-15012078